Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Downgrades Forma Therapeutics Hldgs to Perform

Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.
byBenzinga Newsdesk
September 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Outset Medical Reports Unaudited Q4 And 2023 Revenue, Provides 2024 Revenue And Non-GAAP Gross Margin Guidance; Q4 Revenue Totaled $30.5M Vs $30.13M Est.; Sees FY23 Revenue $130M Vs $130.01M Est.; Sees FY24 Revenue $145M-$153M Vs $149.06M Est.

By Benzinga Newsdesk
January 8, 9:43 AM
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis,today reported unaudited revenue for the fourth quarter

OM